Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Physiological disposition of aerosolized 4-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)sulfonyl)-gamma -oxobenzenebutanoate (L-648,051) in rats

Journal Article · · Drug Metab. Dispos.; (United States)
OSTI ID:6075421
/sup 14/C-labeled 4-((3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl)-sulfonyl)-gamma- oxobenzenebutanoate (L-648,051) was suspended in Freon under pressure and injected into rat lungs via a tracheal cannula. The particle size of the drug was 1 to 5 microns and the mean dose was approximately 0.2 mg/kg. Levels of radioactivity in the lung/trachea declined in a monoexponential manner. Absorption, estimated from radioactivity remaining in the lung and trachea, was 73% in 1 hr and 95% in 4 hr. L-648,051 and its pharmacologically active metabolite L-657,098 (formed by ketoreduction of the butanoic acid moiety of L-648,051) accounted for 96% of the radioactivity in the lung at 10 min after the dose and 91% after 60 min. The lung:plasma concentration ratio of active drug (L-648,051 plus L-657,098) was at least 176:1 at 10 min and 17:1 at 60 min (compared with 1:1 after 2 mg/kg iv) suggesting that aerosol administration of L-648,051 in humans may result in an ideal therapeutic ratio, with high levels of pharmacologically active ingredient in the lung and low levels in the plasma.
Research Organization:
Merck Sharp and Dohme Research Laboratories, West Point, PA (USA)
OSTI ID:
6075421
Journal Information:
Drug Metab. Dispos.; (United States), Journal Name: Drug Metab. Dispos.; (United States) Vol. 16:5; ISSN DMDSA
Country of Publication:
United States
Language:
English